Diapositiva 1
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
![PDF] Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f1e163a466a1e212478a5b9a1f84e7b254a6eba1/8-Table2-1.png "PDF] Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | Semantic Scholar")
PDF] Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | Semantic Scholar
EAU 2019: Conclusions from Recent Oncology Meetings Regarding: Hormone Naïve Prostate Cancer
Presentazione standard di PowerPoint
Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients - ScienceDirect
Thomas E. Keane | Timing of ADT and Chemotherapy
ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial | PLOS Medicine
Focus on 2: The issue of time and combination of RT and hormone/chemotherapy in prostate metastatic setting to obtain better out
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease
Prostate cancer Risk stratification and choice of initial treatment final.pptx
Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X
Uncovering the Right Sequence - ppt download
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting | Oncology and Therapy
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outc
Presentazione standard di PowerPoint
Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in Korea: patterns of care survey (KROG 19-08) - Bae - Annals of Translational Medicine
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Current Oncology | Free Full-Text | Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
